Table 2 Patient characteristics
From: Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival
Variable | n = 76 (100%) |
|---|---|
Gender | |
Male | 41 (53.9) |
Female | 35 (46.1) |
Age (mean; ±SD) [years] | 52.6 (± 14.3) |
Myasthenia gravis | 39 (51.3) |
Type of tumor | |
Primary mediastinal tumor | 55 (72.4) |
Pleural tumor spread | 17 (22.4) |
Mediastinal recurrence | 4 (5.2) |
WHO classification | |
A | 2 (2.6) |
AB | 5 (6.6) |
B1 | 5 (6.6) |
B2 | 28 (36.8) |
Mixed B2/B3 | 8 (10.5) |
B3 | 18 (23.7) |
C (thymus carcinoma) | 10 (13.2) |
Preoperative treatment | |
None | 43 (56.6) |
Induction chemotherapy | 28 (36.8) |
Octreotid/prednisone | 5 (6.6) |
Radiotherapy | 0 (0) |